Boris A. Kallmann
Bamberg, BY 96052, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program.
Journal: Neurology and therapy
Published: September 12, 2023
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
Journal: Expert opinion on pharmacotherapy
Published: August 05, 2022
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Journal: Therapeutic advances in neurological disorders
Published: May 27, 2021
Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
Journal: Der Nervenarzt
Published: May 07, 2021
Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status.
Journal: Therapeutic advances in neurological disorders
Published: March 04, 2021
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Journal: Expert opinion on pharmacotherapy
Published: July 14, 2020
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.
Journal: Therapeutic advances in neurological disorders
Published: September 21, 2018
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Journal: Journal of neurology
Published: February 10, 2018
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM).
Journal: Therapeutic advances in neurological disorders
Published: November 17, 2016
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Journal: Expert opinion on drug delivery
Published: June 23, 2015
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.
Journal: Therapeutic advances in neurological disorders
Published: January 14, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026